1. Market Research

Innovations in Drug Pricing and Reimbursement (2016)

  • February 2016
  • Firstword Pharma
Report ID: 3673824

Summary

Table of Contents

Is the drug pricing bubble about to burst?
Drug costs are becoming unaffordable and draconian cost containment strategies are being employed.

The pharma industry is winning few friends when it comes to drug pricing.

Public, health professional, political and payer hostility is growing worldwide as the prices of new drugs for chronic disease, specialty medicines and even generics grow excessively. How are payers in the US and Europe responding and what cost containment strategies are being – and could be – employed to cap rampant and increasingly unaffordable drug bills?

The pharma industry is winning few friends when it comes to drug pricing.

Public, health professional, political and payer hostility is growing worldwide as the prices of new drugs for chronic disease, specialty medicines and even generics grow excessively. How are payers in the US and Europe responding and what cost containment strategies are being – and could be – employed to cap rampant and increasingly unaffordable drug bills?

“It's pretty discouraging, unfortunately. It makes you think these companies are not really involved in healthcare. I don't think they are…They just are profit centres.”


Answering key questions:


A Fundamental Driver: Why, and to what extent, is the pharma industry’s focus on orphan diseases and high-end biologics creating such an issue for payers?

The End of the Wild West? Freeing Medicare to negotiate drug pricing and PBMs utlilising competitive pressures to lower costs are just some of the solutions to controlling US drug prices– what else is on the table and how extreme might regulators get?


European Variance: Reference pricing, price-volume agreements, tendering, early benefit assessments, HTA cost/benefits assessments, risk-sharing and whole system product value are all being employed – but where and with what success?
Stakeholder Buy-In: Why, and how, might early and open dialogue between industry and payers benefit both parties?
Positive Message? Why is industry failing to get its societal and cost-benefit message heard, and what more could it do to win support?
Same Old, Same Old: In the face of solid profits does industry’s narrative of justifying high drug prices to fund innovation and development need an overhaul?


Risk Sharing: Are risk-sharing, value-based pricing and pricing by indication the best schemes moving forward?
Local Market, Local Problems: Each country has gone its own way in controlling cost – what could they learn from each other and is drug pricing now a regional rather than just a national issue?


With this report you will be able to:


Understand the fundamental research trends that are driving payer concerns and disquiet
Learn which reimbursement strategies are being employed
Assess the multi-country alliances that are forming to negotiate better prices
Appreciate how cost-containment measures vary from country to country
Understand why and how cost containment measures are likely to intensify
Address the pressing need for companies to explain their pricing policies better and support brands with outcomes evidence
Know what payers want and formulate better communication strategies in healthcare. I don't think they are…They just are profit centres.”

Key Topics explored

Is the pharma industry digging its own grave? Price increases above and beyond any economic indicator, price gouging and products which bring little clinical advantage but big cost are creating much ill will and leading to wider and more severe cost containment policies.

Cash strapped payers cannot afford to meet all the demands of aging populations – how can industry positively respond to these concerns?
Even the hitherto free market of the US is now actively seeking ways to control cost. Moves to liberate the negotiating hand of Medicare and a range of other control measures will limit the industry’s scope to act. How far could these developments go?
European countries share the same problems but each has taken a different approach – will consensus emerge and what are the key market variables that pharma should know about?
Drug intervention plays a critical role in controlling disease. Effective medicines and good adherence can improve the patient’s quality of life and significantly reduce overall health expenditure. But these benefits often go unrecognised. Is there a communication issue pharma needs to address?
Biosimilars hold the prospect of lower prices for biologics, but will this sector ever really gain traction in the market?

Expert Contributors
The report is informed through in-depth interviews with payers responsible for drug budgets in the US and EU5 leading economies. To ensure open and critical responses all contributors are anonymous but include:<


Chief pharmacist at NHS Foundation Trust in England
Drug-reimbursement manager for German health insurers
Head of pharmacy at French university hospital
Advisor to Spanish hospitals on pharmacoeconomics and formulary inclusion of new medicines
Director, department of clinical pharmacy in Italy


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.